Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Status:
Recruiting
Trial end date:
2028-10-26
Target enrollment:
Participant gender:
Summary
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy
combined with immunotherapy recently.
On this basis, the investigators intend to conduct a prospective, multicenter phase II
clinical trial to assess whether radiotherapy could further improve the survival of patients
with metastatic esophageal cancer responding to PD-1 Inhibitor plus chemotherapy.
Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular
biological detection (Including Whole Exome Sequencing and proteomics) to explore potential
biomarkers for predicting outcomes, efficacy and toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences